Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
18 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/18/2948213/0/en/Pharmacosmos-Group-and-G1-Therapeutics-Announce-Successful-Closing-of-Tender-Offer.html
20 Apr 2024
// Foo Yun Chee REUTERS
https://www.reuters.com/sustainability/eu-commission-seeks-feedback-vifors-commitments-rivals-disparagement-case-2024-04-19/
10 Sep 2022
// ECONOMIC TIMES
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-buys-rights-from-pharmacosmos-to-sell-drug-to-treat-anemia-in-india-nepal/articleshow/94099973.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
09 Sep 2022
// EXPRESS PHARMA
https://www.expresspharma.in/zydus-in-licenses-critical-drug-for-ckd-patients-from-pharmacosmos/
29 Mar 2022
// M.A. Hemmingsen MEDWATCH
https://medwatch.com/News/Pharma___Biotech/article13868643.ece?utm_campaign=MedWatch%20Newsletter&utm_content=2022-03-28&utm_medium=email&utm_source=medwatch_com
11 Nov 2021
// Nicole DeFeudis ENDPTS
https://endpts.com/too-much-iron-pharmacosmos-is-betting-225m-on-a-new-potential-solution-for-that/
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23246
Submission : 2009-11-06
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19584
Submission : 2006-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1601
Submission : 1970-10-26
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-20
Pay. Date : 2023-10-17
DMF Number : 8364
Submission : 1989-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16030
Submission : 2002-06-24
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2025
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 16, 2025
Details:
Through the acquisition, Pharmacosmos will leverage G1' intellectual property and the addition of Cosela (trilaciclib), which is indicated for treating metastatic triple-negative breast cancer.
Lead Product(s): Trilaciclib
Therapeutic Area: Oncology Brand Name: Cosela
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: G1 Therapeutics, Inc
Deal Size: $405.0 million Upfront Cash: $405.0 million
Deal Type: Acquisition August 07, 2024
Lead Product(s) : Trilaciclib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : G1 Therapeutics, Inc
Deal Size : $405.0 million
Deal Type : Acquisition
Pharmacosmos Group to Acquire G1 Therapeutics
Details : Through the acquisition, Pharmacosmos will leverage G1' intellectual property and the addition of Cosela (trilaciclib), which is indicated for treating metastatic triple-negative breast cancer.
Product Name : Cosela
Product Type : Miscellaneous
Upfront Cash : $405.0 million
August 07, 2024
Details:
Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Perioperative.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Vitamins/Minerals/Inorganic Salts
Recipient: Peking Union Medical College Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2023
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery
Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Perioperative.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 06, 2023
Details:
SP-420 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of beta-Thalassemia.
Lead Product(s): SP-420
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Icon Plc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2023
Lead Product(s) : SP-420
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Icon Plc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia
Details : SP-420 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of beta-Thalassemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 23, 2023
Details:
MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Brand Name: MonoFerric
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Zydus Lifesciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 09, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Acquisition
Zydus Buys Rights from Pharmacosmos to Sell Drug to Treat Anemia in India, Nepal
Details : MonoFerric injection having Ferric derisomaltose, is a rapid, single dose intravenous therapy used for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used.
Product Name : MonoFerric
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
September 09, 2022
Details:
Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Genital Neoplasms, Female.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts
Recipient: Alberta Health services
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Genital Neoplasms, Female.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 20, 2022
Details:
Monoferric (Ferric Derisomaltose) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Brand Name: Monoferric
Study Phase: Phase IVProduct Type: Vitamins/Minerals/Inorganic Salts
Recipient: Brigham and Women's Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Preoperative Monoferric for Abdominal Surgery
Details : Monoferric (Ferric Derisomaltose) is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia.
Product Name : Monoferric
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 28, 2022
Details:
Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2022
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 05, 2022
Details:
Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Iron-Deficiency.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: P. Noordzij
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2021
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : P. Noordzij
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
Details : Ferric Derisomaltose is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Iron-Deficiency.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 04, 2021
Details:
Monofer® is the first of the latest generation of innovative IV irons to be made available to patients in the Chinese health care system and is expected to expand the use of IV irons across multiple therapeutic areas.
Lead Product(s): Ferric Derisomaltose
Therapeutic Area: Hematology Brand Name: Monofer
Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 29, 2021
Lead Product(s) : Ferric Derisomaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacosmos' Monoferric® (Ferric Derisomaltose) Injection is Approved by the US FDA for the Trea...
Details : Monofer® is the first of the latest generation of innovative IV irons to be made available to patients in the Chinese health care system and is expected to expand the use of IV irons across multiple therapeutic areas.
Product Name : Monofer
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Dosage Form : SOLUTION; INTRAVENOUS
Proprietary Name : MONOFERRIC
Dosage Strength : 100MG/ML (100MG/ML)
Approval Date : 2020-01-16
Application Number : 208171
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Dosage Form : SOLUTION; INTRAVENOUS
Proprietary Name : MONOFERRIC
Dosage Strength : 500MG/5ML (100MG/ML)
Approval Date : 2020-01-16
Application Number : 208171
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Dosage Form : SOLUTION; INTRAVENOUS
Proprietary Name : MONOFERRIC
Dosage Strength : 1GM/10ML (100MG/ML)
Approval Date : 2020-01-16
Application Number : 208171
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Dosage Form : POWDER; INTRAVENOUS
Proprietary Name : COSELA
Dosage Strength : EQ 300MG BASE/VIAL
Approval Date : 2021-02-12
Application Number : 214200
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Europe
Regulatory Info : Cancelled
Registration Country : Spain
Dosage Form : Injectable And Perfusion Solut...
Dosage Strength : 100MG
Packaging :
Brand Name : Single Iron
Approval Date : 2012-03-16
Application Number : 72381
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection/Infusio...
Dosage Strength : 50mg/ml
Packaging :
Brand Name : Cosmofer
Approval Date : 05/07/2006
Application Number : 20060226000011
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Cancelled
Registration Country : Spain
Dosage Form : Solution For Perfusion And Inj...
Dosage Strength : 50MG
Packaging :
Brand Name : Cosmofer
Approval Date : 2006-12-12
Application Number : 68243
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Injectable Solution
Dosage Strength : 50mg/ml
Packaging :
Brand Name : Diafer
Approval Date : 22/03/2013
Application Number : 20120124000060
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection/Infusio...
Dosage Strength : 100mg/ml
Packaging :
Brand Name : Monofer
Approval Date : 22/01/2010
Application Number : 20080716000093
Regulatory Info : Approved
Registration Country : Sweden
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
Regulatory Info : Prescription
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 100MG/ML
Packaging : 1/5/10ML
Brand Name : MONOFERRIC
Approval Date :
Application Number : 2477777
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : NON-PRESCRIPTION DRUGS
Registration Country : Canada
Dosage Form : SOLUTION
Dosage Strength : 200MG/ML
Packaging :
Brand Name : SOLOFER
Approval Date :
Application Number : 2511843
Regulatory Info : NON-PRESCRIPTION DRUGS
Registration Country : Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Pharma Cosmos is a supplier offers 8 products (APIs, Excipients or Intermediates).
Find a price of Dextrans bulk with DMF, CEP offered by Pharma Cosmos
Find a price of Dextrans bulk with CEP offered by Pharma Cosmos
Find a price of Ferric Derisomaltose bulk with JDMF offered by Pharma Cosmos
Find a price of Iron Dextran bulk with DMF offered by Pharma Cosmos
Find a price of Iron bulk offered by Pharma Cosmos
Find a price of Iron Dextran bulk offered by Pharma Cosmos
Find a price of IRON(III)-HYDROXIDE OLIGOSACCHARIDE COMPLEX bulk offered by Pharma Cosmos
Find a price of Dextrans bulk offered by Pharma Cosmos
Share 
